Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- New guideline widens hypertension definition, incorporates CV risk
-
- 2017: Guidelines take prominence; much less focus on new drug discoveries Carl J. Pepine, MD, MACC
- 2 decades of intervention
- CVD in cancer survivors: Stick to the basics of prevention Kristopher Swiger, MD; Javid J. Moslehi, MD
- FDA approves evolocumab for prevention of MI, stroke, coronary revascularization
- Abdominal obesity confers mortality risk in HFpEF
- ACC advises on bleeding episodes with oral anticoagulants
- Afternoon surgical AVR confers fewer cardiac events
- CV health screenings rose after implementation of ACA
-
- ECG abnormalities common in NBA athletes
- Exercise confers benefit in HFpEF
- Higher thyroid hormone levels linked to atherosclerotic CVD, mortality
- HYDRA: Rosuvastatin reduces LDL in children with homozygous FH
- Increased levels of any physical activity reduce mortality, CVD risk
- Noninvasive radioablation reduces burden in ventricular tachycardia
- Perioperative myocardial injury common from noncardiac surgery
- Peripartum cardiomyopathy more common in black women
-
- Cardiology Today asked the Editorial Board for their thoughts on the top stories of 2017
- Looking ahead: Top trends for 2018
- Burnout common in cardiologists, especially women
- Evolocumab effective regardless of PAD, MI status
- PRESERVE: No benefit of sodium bicarbonate, acetylcysteine for prevention of mortality, renal outcomes after angiography
- Ralinepag improves pulmonary vascular resistance in PAH
- STEMI Accelerator-2: Coordinated emergency systems of care reduce treatment times, mortality
- Telepharmacy intervention yields modest effect on medication adherence among patients with cardiometabolic diseases
-
- ICHECK’D: Mnemonic approach assists in caring for patients receiving direct oral anticoagulant Elizabeth Renner, PharmD; Deborah DeCamillo, RN, BSN
- Trial Scoreard: ALPS
- Trial Scoreard: ATTRACT
- Trial Scoreard: BRUISE CONTROL-2
- Trial Scoreard: CRESCENT-II
- Trial Scoreard: DECIDE-LVAD
- Trial Scoreard: HEROIC
- Trial Scoreard: PREMIUM
-
- Trial Scoreard: PRESERVE
- A tribute to Emile Mohler, MD Andrew E. Epstein, MD, FAHA, FACC, FHRS